Edgewise Therapeutics(EWTX)
$43.68-2.25 (-4.90%)
EWTX
Edgewise Therapeutics financials statements
$43.68
At close:-2.25 (-4.90%)
Want to see EWTX full AI Analyst Report?
Edgewise Therapeutics (EWTX) Ratios
440 Followers
Edgewise Therapeutics Ratios
EWTX's free cash flow for Q3 2026 was $-77.27M. For the 2026 fiscal year, EWTX's free cash flow was decreased by $-17.00K and operating cash flow was $-77.25M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 |
| Quick Ratio | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 |
| Cash Ratio | 2.23 | 1.75 | 5.13 | 1.33 | 1.48 |
| Solvency Ratio | -5.45 | -4.77 | -4.64 | -3.29 | -3.92 |
| Operating Cash Flow Ratio | -5.25 | -4.57 | -5.48 | -3.17 | -3.18 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 513.04M | $ 447.88M | $ 305.79M | $ 336.61M | $ 272.92M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.06 | 1.07 | 1.06 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -17.70 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -17.83 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.05 | 0.08 | 0.16 | 0.00 |
| Net Debt to EBITDA | 0.35 | 0.28 | 0.72 | 0.25 | 0.36 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 87.66% | 84.25% | 87.59% | 94.39% | 99.07% |
| Return on Assets (ROA) | -30.36% | -27.49% | -29.46% | -18.43% | -15.01% |
| Return on Equity (ROE) | -32.13% | -29.14% | -31.42% | -19.51% | -15.60% |
| Return on Capital Employed (ROCE) | -36.44% | -34.31% | -35.38% | -20.44% | -15.73% |
| Return on Invested Capital (ROIC) | -36.37% | -34.23% | -35.27% | -20.41% | -15.73% |
| Return on Tangible Assets | -30.36% | -27.49% | -29.46% | -18.43% | -15.01% |
| Earnings Yield | -6.57% | -5.42% | -14.37% | -14.12% | -5.66% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -967.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 967.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.40 | -1.18 | -1.44 | -0.98 | -0.68 |
| Free Cash Flow Per Share | -1.40 | -1.19 | -1.53 | -1.09 | -0.69 |
| Dividend Paid and CapEx Coverage Ratio | -561.78 | -83.10 | -16.00 | -9.49 | -50.16 |
| Capital Expenditure Coverage Ratio | -561.78 | -83.10 | -16.00 | -9.49 | -50.16 |
| Operating Cash Flow Coverage Ratio | -36.04 | -23.02 | -16.98 | -11.94 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -5.64% | -4.47% | -14.01% | -12.14% | -4.52% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -15.23 | -18.41 | -6.96 | -7.08 | -17.67 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.89 | 5.37 | 2.19 | 1.38 | 2.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -17.73 | -22.36 | -7.14 | -8.24 | -22.13 |
| Price-to-Operating Cash Flow Ratio | -17.76 | -22.63 | -7.58 | -9.10 | -22.57 |
| Price-to-Earnings Growth (PEG) Ratio | -1.23 | 2.41 | -0.28 | -0.15 | -0.12 |
| Enterprise Value Multiple | -15.09 | -18.48 | -5.47 | -6.49 | -17.25 |
| Enterprise Value | 2.50B | 2.43B | 616.45M | 461.54M | 740.80M |
| EV to EBITDA | -15.09 | -18.48 | -5.47 | -6.49 | -17.25 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -17.34 | -22.03 | -6.31 | -7.93 | -21.68 |
| EV to Operating Cash Flow | -17.37 | -22.29 | -6.70 | -8.77 | -22.11 |
| Tangible Book Value Per Share | 5.07 | 4.97 | 5.00 | 6.47 | 5.54 |
| Shareholders’ Equity Per Share | 5.07 | 4.97 | 5.00 | 6.47 | 5.54 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.88 | 0.94 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.86 | 0.81 | 0.92 | 0.78 | 0.78 |
Currency in USD

